Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZSSW21040164
- Development stage
- Unknown
- Lead developer
- Genuine Biotech
01
Overview
ZSSW21040164: sourced facts only. name: "ZSSW21040164, an orally available human STING agonist, emerged as a crucial finding." [DOI:10.1158/1538-7445.am2025-6983]; target: "ZSSW21040164, an orally available human STING agonist, emerged as a crucial finding." [DOI:10.1158/1538-7445.am2025-6983]; developer: "Henan Genuine Biotech Limited Inc, Henan, China." [DOI:10.1158/1538-7445.am2025-6983]; stage: "In murine tumor models bearing H22, MC38, and CT-26 tumors, oral administration of ZSSW21040164 was well-tolerated and had a significant anti-tumor effect with more tumors achieved complete remission, which accompanied by the establishment of durable antitumor immunity." [DOI:10.1158/1538-7445.am2025-6983]
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on ZSSW21040164.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZSSW21040164.